SCHEMBL5458239

SCHEMBL5458239

CCOc1ccc(Cl)cc1NC(=O)Nc1ccc(N2CCN(C(=O)OC(C)(C)C)CC2)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 8/20 0.52
SMN1; SMN2 Q16637 5/20 0.52
MEN1 O00255 3/20 0.52
KMT2A Q03164 3/20 0.52
TSHR P16473 2/20 0.52
LMNA P02545 4/20 0.52
HPGD P15428 2/20 0.52
MAPK1 P28482 1/20 0.52
HTT P42858 2/20 0.50
NPSR1 Q6W5P4 1/20 0.50
NAMPT P43490 1/20 0.50
ALDH1A1 P00352 3/20 0.49
NPC1 O15118 2/20 0.49
HSD17B10 Q99714 1/20 0.46
RBP4 P02753 1/20 0.46
GAA P10253 1/20 0.46
CCNK O75909 1/20 0.45
CCNA2 P20248 1/20 0.45
CDK2 P24941 1/20 0.45
CCND3 P30281 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5458258 0.90 MAPT (0.53) MAPTSMN1; SMN2MEN1KMT2ATSHR
SCHEMBL5457870 0.90 RBP4 (0.58) MAPTSMN1; SMN2MEN1KMT2ATSHR
SCHEMBL5466120 0.89 MAPT (0.50) MAPTSMN1; SMN2MEN1KMT2ATSHR
SCHEMBL5465465 0.88 WNT3A (0.51) MAPTSMN1; SMN2MEN1KMT2ATSHR
SCHEMBL5469328 0.88 MAPT (0.56) MAPTSMN1; SMN2MEN1KMT2ATSHR
SCHEMBL5462055 0.87 NAMPT (0.58) MAPTSMN1; SMN2MEN1KMT2ATSHR
SCHEMBL5467284 0.86 MAPT (0.56) MAPTSMN1; SMN2MEN1KMT2ATSHR
SCHEMBL5460919 0.86 NAMPT (0.53) MAPTSMN1; SMN2MEN1KMT2ATSHR
SCHEMBL5457926 0.85 MAPT (0.56) MAPTSMN1; SMN2MEN1KMT2ATSHR
SCHEMBL5473080 0.83 SMN1; SMN2 (0.55) MAPTSMN1; SMN2MEN1KMT2ATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070249620-A1 Urea Derivative SANKYO COMPANY, LIMITED (JP) 2007-10-25 US disclosed
EP-1764360-A1 UREA DERIVATIVE Sankyo Company, Limited (JP) 2007-03-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070249620-A1 Urea Derivative UGP2, SLC14A1, DGAT1 MAPT 758/4885SMN1; SMN2 4424/4885MEN1 1828/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.